Table 3.

Demographics, Clinical Features, Imaging Abnormalities, and Outcome are Presented for Patients with Intracerebral Hemorrhage

Demographics
n	6
Median age (IQR), years	70.5(45–79)
Male gender	50% (3/6)
Immunosuppression	33.33% (2/6)
Days from Herpes zoster infection to the occurrence of neurologic symptoms (mean), n=5	8(1–16)
Clinical features
Headache	66.67% (4/6)
Fever	66.67% (4/6)
Cognitive impairment	83.33% (5/6)
Hemiplegia	66.67% (4/6)
Diagnostic testing
PCR positive for VZV(CSF) only	33.33% (2/6)
anti-VZV IgG positive for VZV(CSF) only	16.67% (1/6)
Both PCR and anti-VZV IgG positive for VZV(CSF)	16.67% (1/6)
Both anti-VZV IgG positive for VZV CSF and serum	33.33% (2/6)
Neuroimaging
Evidence for vasculitis	16.67% (1/6)
Affected areas of circulation
Anterior	0% (0/6)
Posterior	16.67% (1/6)
Both anterior and posterior	83.33% (5/6)
Distribution of lesions
Single	33.33% (2/6)
Multiple	66.67% (4/6)
Treatment
Acyclovir treatment	100% (5/5)
Steroid treatment	40% (2/5)
Outcome
Good outcome (mRS 0–2)	40% (2/5)
Unfavorable outcome (mRS 3–5)	0% (0/5)
Death	60% (3/5)